Contact
searchSearch
HMP Global
Login

News

Benjamin Rolles, MD
Conference Coverage
Impact of Treatment Response to Hypomethylating Agents and Time-to-Transplant Status on Outcomes Among Patients With MDS
01/13/2025
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more...
01/13/2025
Oncology
News
Eltrombopag and Cyclosporin A Demonstrate Beneficial Outcomes as Frontline Treatment for Patients With Severe Aplastic Anemia
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
News
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Potential Minor Criteria for Polycythemia Vera Diagnosis
08/22/2023
Amber Denham
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera
08/09/2023
Amber Denham
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology
News
Alternative Dosing Regimen of Ropeginterferon Alfa-2b Demonstrates High Efficacy, Tolerability Among Patients With Polycythemia Vera
07/14/2023
Gina Tomaine
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of...
07/14/2023
Oncology
News
Ruxolitinib Treatment Effective, Safe for Patients With Newly Diagnosed Polycythemia Vera
05/05/2023
Gina Tomaine
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to...
05/05/2023
Oncology
News
Momelotinib Improved Anemia Measures, Spleen Response, and Overall Safety Among Patients With Myelofibrosis
04/21/2023
Jordan Kadish
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial,...
04/21/2023
Oncology
News
Low-Intensity Regimens for Sickle Cell Disease Transplantation Associated With Risk of Secondary Neoplasms
03/13/2023
Jordan Kadish
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for...
03/13/2023
Oncology
Conference Coverage
Ropeginterferon Alfa-2b Yielded Higher Hematologic and Molecular Response Rates Among Patients With Low-Risk vs High-Risk Polycythemia Vera
02/27/2023
Jordan Kadish
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that...
02/27/2023
Oncology
Conference Coverage
Ropeginterferon Alfa-2b Yielded Higher Hematologic and Molecular Response Rates Among Patients With Low-Risk vs High-Risk Polycythemia Vera
02/27/2023
Jordan Kadish
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that...
02/27/2023
Oncology

Recent News

News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Stephanie Holland
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use